Lenacapavir has been named Science Journal’s 2024 Breakthrough of the Year. This HIV prevention drug has shown high rates of efficacy in preventing infections in recent trials. Even better, it offers long-lasting protection, with effects lasting up to six months, making it a game-changer for HIV prevention, especially in high-risk communities.
The UCLA Vine Street Clinic is a participating site in this exciting research.
What makes Lenacapavir stand out is that it’s taken less often than other HIV medications, which could lead to better treatment outcomes and make HIV care more accessible. This breakthrough is a huge step forward in both HIV treatment and prevention.
Looking ahead, Lenacapavir has the potential to play a key role in the global fight against HIV, helping to reduce infections around the world.
To learn more about why this innovative drug earned such a big honor, check out the full article in .
You can also check out the latest research on lenacapavir in the CBAM’s Dr. Jesse Clark is an author on the paper.
